Organonitro thioether compounds and medical uses thereof
The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof. Another aspect of the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and an organonitro thioether compound described herein, such as a compound of Formula I or II. Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of an organonitro thioether compound described herein, such as a compound of Formula I or II, to treat the cancer.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an organonitro compound of Formula I or II, wherein Formula I is represented by:
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A 1 is N or —C(R 5 )—;
A 2 is —C(O)— or —(C(R 6 ) 2 ) x C(O)(C(R 6 ) 2 ) x —;
R 1 is C 1 -C 5 alkyl;
R 2 and R 3 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 2 and R 3 are taken together with the carbon atom to which they are attached to form a carbocyclic ring;
R 4 is C 1 -C 5 alkyl substituted with one X 1 group and one X 2 group; wherein X 1 is —N(R 7 )(R 8 ), —N(R 7 )C(O)—C 1 -C 5 alkyl, —N(R 7 )C(O)—C 3 -C 7 cycloalkyl, —N(R 7 )C(O)-aryl, —N(R 7 )C(O)—aralkyl, or —N(R 7 )C(O)—(C 1 -C 5 alkylene)-C(H)[N(R 7 )(R 8 )]—CO 2 R 9 ; and X 2 is —CO 2 R 10 or —C(O)N(R 7 )—(C 1 -C 5 alkylene)-CO 2 R 10 ;
R 5 is hydrogen or C 1 -C 5 alkyl;
R 6 represents independently for each occurrence C 1 -C 6 alkyl, C 1 -C 5 haloalkyl, aryl, or aralkyl;
R 7 and R 8 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 7 and R 8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring;
R 9 and R 10 each represent independently hydrogen, C 1 -C 5 alkyl, C 3 -C 7 cycloalkyl, aryl, or aralkyl;
n, p, and t are independently 1, 2, or 3; and
m and x each represent independently for each occurrence 0, 1, 2, or 3;
Formula II is represented by:
or a pharmaceutically acceptable salt or solvate thereof: wherein:
A 1 is —N(R 5 )— or —C(R 2 )(R 3 )—;
A 2 is —C(O)— or —(C(R 6 ) 2 ) x C(O)(C(R 6 ) 2 ) x —;
R 1 is C 1 -C 5 alkyl or C 3 -C 7 cycloalkyl;
R 2 and R 3 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 2 and R 3 are taken together with the carbon atom to which they are attached to form a carbocyclic ring;
R 4 is C 1 -C 5 alkyl substituted with one X 1 group and one X 2 group; wherein X 1 is —N(R 7 )(R 8 ), —N(R 7 )C(O)—C 1 -C 5 alkyl, —N(R 7 )C(O)—C 3 -C 7 cycloalkyl, —N(R 7 )C(O)-aryl, —N(R 7 )C(O)—aralkyl, or —N(R 7 )C(O)—(C 1 -C 5 alkylene)-C(H)[N(R 7 )(R 8 )]—CO 2 R 9 ; and X 2 is —CO 2 R 10 or —C(O)N(R 7 )—(C 1 -C 5 alkylene)-CO 2 R 10 ;
R 5 is hydrogen or C 1 -C 5 alkyl;
R 6 represents independently for each occurrence C 1 -C 5 alkyl, C 1 -C 5 haloalkyl, aryl, or aralkyl;
R 7 and R 8 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 7 and R 8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring;
R 9 and R 10 each represent independently hydrogen, C 1 -C 5 alkyl, C 3 -C 7 cycloalkyl, aryl, or aralkyl;
t and v are independently 1, 2, or 3; and
x represents independently for each occurrence 0, 1, 2, or 3.
2. The pharmaceutical composition of claim 1 , wherein the organonitro compound is a compound of Formula I.
3. The pharmaceutical composition of claim 2 , wherein A 1 is N.
4. The pharmaceutical composition of claim 3 , wherein A 2 is —C(O)—.
5. The pharmaceutical composition of claim 4 , wherein R 2 and R 3 are hydrogen.
6. The pharmaceutical composition of claim 5 , wherein m is 0.
7. The pharmaceutical composition of claim 4 , wherein n is 2.
8. The pharmaceutical composition of claim 7 , wherein t is 1.
9. The pharmaceutical composition of claim 7 , wherein R 4 is —CH 2 C(H)(X 1 )X 2 .
10. The pharmaceutical composition of claim 9 , wherein X 1 is —N(R 7 )(R 8 ), —N(R 7 )C(O)—C 1 -C 5 alkyl, or —N(R 7 )C(O)—(C 1 -C 5 alkylene)-C(H)[N(R 7 )(R 8 )]CO 2 R 9 .
11. The pharmaceutical composition of claim 9 , wherein X 1 is —NH 2 , —N(H)C(O)CH 3 , or —N(H)C(O)CH 2 CH 2 C(H)(NH 2 )—CO 2 H; and X 2 is —CO 2 H, —CO 2 Me, or —C(O)N(H)CH 2 CO 2 H.
12. The pharmaceutical composition of claim 9 , wherein X 1 is —NH 2 or —N(H)C(O)CH 2 CH 2 C(H)(NH 2 )—CO 2 H; and X 2 is —CO 2 H or —C(O)N(H)CH 2 CO 2 H.
13. The pharmaceutical composition of claim 7 , wherein R 4 is
14. The pharmaceutical composition of claim 1 , wherein the organonitro compound is a compound of Formula I-A:
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A 1 is N or C(H);
R 1 represents independently for each occurrence hydrogen or methyl;
R 4 is C 1 -C 5 alkyl substituted with one X 1 group and one X 2 group; wherein X 1 is —NH 2 , —N(H)C(O)—C 1 -C 5 alkyl, or —N(H)C(O)—(C 1 -C 5 alkylene)-C(H)(NH 2 )—CO 2 H; and X 2 is —CO 2 H, —CO 2 —C 1 -C 5 alkyl, or —C(O)N(H)CH 2 CO 2 H; and
p represents independently for each occurrence 1 or 2.
15. The pharmaceutical composition of claim 14 , wherein R 4 is
16. The pharmaceutical composition of claim 1 , wherein the organonitro compound is one of the following:
or a pharmaceutically acceptable salt thereof.
17. An isolated compound of Formula I, wherein Formula 1 is represented by:
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A 1 is N or —C(R 5 )—;
A 2 is —C(O)— or —(C(R 6 ) 2 ) x C(O)(C(R 6 ) 2 ) x —;
R 1 is C 1 -C 5 alkyl;
R 2 and R 3 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 2 and R 3 are taken together with the carbon atom to which they are attached to form a carbocyclic ring;
R 4 is C 1 -C 5 alkyl substituted with one X 1 group and one X 2 group; wherein X 1 is —N(R 7 )(R 8 ), —N(R 7 )C(O)—C 1 -C 5 alkyl, —N(R 7 )C(O)—C 3 -C 7 cycloalkyl, —N(R 7 )C(O)-aryl, —N(R 7 )C(O)-aralkyl, or —N(R 7 )C(O)—(C 1 -C 5 alkylene)-C(H)[N(R 7 )(R 8 )]—CO 2 R 9 ; and X 2 is —CO 2 R 10 or —C(O)N(R 7 )—(C 1 -C 5 alkylene)-CO 2 R 10 ;
R 5 is hydrogen or C 1 -C 5 alkyl;
R 6 represents independently for each occurrence C 1 -C 6 alkyl, C 1 -C 5 haloalkyl, aryl, or aralkyl;
R 7 and R 8 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 7 and R 8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring;
R 9 and R 10 each represent independently hydrogen, C 1 -C 5 alkyl, C 3 -C 7 cycloalkyl, aryl, or aralkyl;
n, p, and t are independently 1, 2, or 3; and
m and x each represent independently for each occurrence 0, 1, 2, or 3.
18. A compound of Formula II, wherein Formula II is represented by:
or a pharmaceutically acceptable salt or solvate thereof: wherein:
A 1 is —N(R 5 )— or —C(R 2 )(R 3 )—;
A 2 is —C(O)— or —(C(R 6 ) 2 ) x C(O)(C(R 6 ) 2 ) x —;
R 1 is C 1 -C 5 alkyl or C 3 -C 7 cycloalkyl;
R 2 and R 3 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 2 and R 3 are taken together with the carbon atom to which they are attached to form a carbocyclic ring;
R 4 is C 1 -C 5 alkyl substituted with one X 1 group and one X 2 group; wherein X 1 is —N(R 7 )(R 8 ), —N(R 7 )C(O)—C 1 -C 5 alkyl, —N(R 7 )C(O)—C 3 -C 7 cycloalkyl, —N(R 7 )C(O)-aryl, —N(R 7 )C(O)-aralkyl, or —N(R 7 )C(O)—(C 1 -C 5 alkylene)-C(H)[N(R 7 )(R 8 )]CO 2 R 9 ; and X 2 is —CO 2 R 10 or —C(O)N(R 7 )—(C 1 -C 5 alkylene)-CO 2 R 10 ;
R 5 is hydrogen or C 1 -C 5 alkyl;
R 6 represents independently for each occurrence C 1 -C 5 alkyl, C 1 -C 5 haloalkyl, aryl, or aralkyl;
R 7 and R 8 each represent independently for each occurrence hydrogen or C 1 -C 5 alkyl; or R 7 and R 8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring;
R 9 and R 10 each represent independently hydrogen, C 1 -C 5 alkyl, C 3 -C 7 cycloalkyl, aryl, or aralkyl;
t and v are independently 1, 2or 3; and
x represents independently for each occurrence 0, 1, 2 or 3.
19. A method of treating cancer in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 1 .
20. The method of claim 19 , wherein the cancer is a solid tumor.
21. The method of claim 19 , wherein the cancer is brain cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.
22. The method of claim 19 , further comprising exposing the cancer to radiation.
23. The method of claim 19 , further comprising administering a chemotherapeutic agent to the patient.
24. The method of claim 19 , wherein the patient is a human.